Georg Goliasch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5372425/publications.pdf

Version: 2024-02-01

80 papers

1,549 citations

394421 19 h-index 36 g-index

80 all docs 80 docs citations

80 times ranked

2002 citing authors

#	Article	IF	CITATIONS
1	Severe tricuspid regurgitation: prognostic role of right heart remodelling and pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 246-254.	1.2	12
2	Access site complications of postcardiotomy extracorporeal life support. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1546-1558.e8.	0.8	9
3	Circulating dipeptidyl peptidase (cDPP3)—A marker for endâ€stage heart failure?. Journal of Internal Medicine, 2022, 291, 886-890.	6.0	2
4	Fate of patients weaned from post-cardiotomy extracorporeal life support. European Journal of Cardio-thoracic Surgery, 2022, 61, 1178-1185.	1.4	9
5	Transcatheter Versus Surgical Valve Repair in Patients with Severe Mitral Regurgitation. Journal of Personalized Medicine, 2022, 12, 90.	2.5	2
6	Guideline directed <i>medical</i> therapy and reduction of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2022, 23, 755-764.	1.2	9
7	Cerebral Protection in TAVRâ€"Can We Do Without? A Real-World All-Comer Intention-to-Treat Studyâ€"Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. Journal of Personalized Medicine, 2022, 12, 320.	2.5	5
8	Malnutrition outweighs the effect of the obesity paradox. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1477-1486.	7.3	12
9	Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2022, 15, .	2.6	12
10	Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement. European Heart Journal Cardiovascular Imaging, 2021, 22, 1045-1053.	1.2	14
11	Increased concentrations of bioactive adrenomedullin subsequently to angiotensinâ€receptor/neprilysinâ€inhibitor treatment in chronic systolic heart failure. British Journal of Clinical Pharmacology, 2021, 87, 916-924.	2.4	13
12	A machine learning algorithm supports ultrasound-na \tilde{A} -ve novices in the acquisition of diagnostic echocardiography loops and provides accurate estimation of LVEF. International Journal of Cardiovascular Imaging, 2021, 37, 577-586.	1.5	37
13	Natural Course of Nonsevere Secondary Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2021, 34, 13-19.	2.8	19
14	Diagnostic assessment and procedural imaging for transcatheter edge-to-edge tricuspid valve repair: a step-by-step guide. European Heart Journal Cardiovascular Imaging, 2021, 22, 8-10.	1.2	9
15	The Paradox of Secondary Mitral Regurgitation. JACC: Cardiovascular Imaging, 2021, 14, 740-741.	5. 3	5
16	Secondary mitral regurgitationâ€"Insights from microRNA assessment. European Journal of Clinical Investigation, 2021, 51, e13381.	3.4	4
17	Volume Status Impacts CMR–Extracellular Volume Measurements and Outcome in AS Undergoing TAVR. JACC: Cardiovascular Imaging, 2021, 14, 516-518.	5.3	7
18	Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 34.	6.8	20

#	Article	IF	CITATIONS
19	Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists. ESC Heart Failure, 2021, 8, 1408-1416.	3.1	7
20	Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction. Wiener Klinische Wochenschrift, 2021, 133, 780-785.	1.9	4
21	Neprilysin inhibition does not alter dynamic of proenkephalinâ€A 119â€159 and proâ€substance P in heart failure. ESC Heart Failure, 2021, 8, 2016-2024.	3.1	3
22	Myocardial Angiotensin Metabolism in End-Stage HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1731-1743.	2.8	18
23	Prognostic Value of Echocardiographic Right Ventricular Function Parameters in the Presence of Severe Tricuspid Regurgitation. Journal of Clinical Medicine, 2021, 10, 2266.	2.4	3
24	Percutaneous bail-out in severe acute mitral regurgitation: when surgery is not an option. European Heart Journal - Case Reports, 2021, 5, ytab207.	0.6	0
25	Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ, The, 2021, 373, n1421.	6.0	32
26	Impact of sex on the management and outcome of aortic stenosis patients: a female aortic valve stenosis paradox, and a call for personalized treatments?. European Heart Journal, 2021, 42, 2692-2694.	2.2	5
27	Principal Morphomic and FunctionalÂComponents of Secondary MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2021, 14, 2288-2300.	5.3	26
28	Clinical Impact of Pre-Procedural Percutaneous Coronary Intervention in Low- and Intermediate-Risk Transcatheter Aortic Valve Replacement Recipients. Journal of Personalized Medicine, 2021, 11, 633.	2.5	1
29	Durable Reduction of Mitral Regurgitation After 2 Years. JACC: Cardiovascular Interventions, 2021, 14, 1549-1550.	2.9	0
30	Mitral regurgitation tips the scales in acute or worsening heart failure. European Journal of Heart Failure, 2021, 23, 1763-1764.	7.1	0
31	Heart Failure with Preserved Ejection Fraction after Leftâ€sided Valve Surgery: Prevalent and Relevant. European Journal of Heart Failure, 2021, , .	7.1	5
32	Secondary tricuspid regurgitation: neglected no more!. European Heart Journal Cardiovascular Imaging, 2021, 22, 166-167.	1.2	1
33	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. Frontiers in Cardiovascular Medicine, 2021, 8, 725903.	2.4	12
34	Relevance of Neutrophil Neprilysin in Heart Failure. Cells, 2021, 10, 2922.	4.1	5
35	Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement. European Heart Journal Cardiovascular Imaging, 2021, 22, 1295-1303.	1.2	12
36	A Real World 10-Year Experience With Vascular Closure Devices and Large-Bore Access in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation. Frontiers in Cardiovascular Medicine, 2021, 8, 791693.	2.4	3

#	Article	IF	CITATIONS
37	Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. Scientific Reports, 2020, 10, 15568.	3.3	60
38	The Authors Reply: JACC: Cardiovascular Imaging, 2020, 13, 1458.	5.3	0
39	An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation. Journal of Personalized Medicine, 2020, 10, 233.	2.5	1
40	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. JACC Basic To Translational Science, 2020, 5, 715-726.	4.1	9
41	Current Insights Into Secondary Mitral Regurgitation—Workup and Management. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	0
42	Simultaneous transcatheter mitral valve-in-mitral annular calcification and aortic valve-in-valve implantation: benefits of advanced multimodality imaging. European Heart Journal Cardiovascular Imaging, 2020, 21, 1433-1433.	1.2	0
43	Tricuspid regurgitation secondary to heart failure: more pieces to solve the puzzle. European Journal of Heart Failure, 2020, 22, 1814-1816.	7.1	1
44	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 891.	5.3	0
45	Increased resting heart rate and prognosis in treatmentâ€naÃ⁻ve unselected cancer patients: results from a prospective observational study. European Journal of Heart Failure, 2020, 22, 1230-1238.	7.1	23
46	The inflammationâ€based modified Glasgow prognostic score is associated with survival in stable heart failure patients. ESC Heart Failure, 2020, 7, 654-662.	3.1	23
47	Interventional treatment of tricuspid regurgitation. Wiener Klinische Wochenschrift, 2020, 132, 57-60.	1.9	1
48	Systematic Evaluation of Systemic Right Ventricular Function. Journal of Clinical Medicine, 2020, 9, 107.	2.4	5
49	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. European Heart Journal, 2020, 41, 2799-2810.	2.2	45
50	Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. Journal of Clinical Medicine, 2020, 9, 938.	2.4	3
51	Blood urea nitrogen has additive value beyond estimated glomerular filtration rate for prediction of long-term mortality in patients with acute myocardial infarction. European Journal of Internal Medicine, 2019, 59, 84-90.	2.2	28
52	Papillary Muscle Dyssynchrony-Mediated Functional Mitral Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 1728-1737.	5.3	21
53	Global regurgitant volume: approaching the critical mass in valvular-driven heart failure. European Heart Journal Cardiovascular Imaging, 2019, 21, 168-174.	1.2	5
54	The Authors Reply. JACC: Cardiovascular Imaging, 2019, 12, 1114.	5.3	0

#	Article	IF	CITATIONS
55	Disproportionate Functional MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 2088-2090.	5.3	32
56	Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure. European Journal of Clinical Investigation, 2019, 49, e13159.	3.4	10
57	A Contemporary Definition of Periprocedural Myocardial Injury After Percutaneous Coronary Intervention of Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2019, 12, 1915-1923.	2.9	22
58	GDFâ€15 in solid vs nonâ€solid treatmentâ€naà ve malignancies. European Journal of Clinical Investigation, 2019, 49, e13168.	3.4	10
59	Reply. Journal of the American College of Cardiology, 2019, 74, 1845-1847.	2.8	3
60	A Unifying Concept for the QuantitativeÂAssessment of SecondaryÂMitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 2506-2517.	2.8	86
61	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naÃ-ve cancer patients. Scientific Reports, 2019, 9, 2554.	3.3	18
62	Aortic stenosis is an independent predictor for outcome in patients with in-hospital cardiac arrest. Resuscitation, 2019, 137, 156-160.	3.0	4
63	Syncope. JACC: Cardiovascular Imaging, 2019, 12, 225-232.	5.3	22
64	Natural History of FunctionalÂTricuspidÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 389-397.	5.3	102
65	Natural history of bivalvular functional regurgitation. European Heart Journal Cardiovascular Imaging, 2019, 20, 565-573.	1.2	9
66	Sex-Related Differences in Low-Gradient, Low–Ejection Fraction Aortic Stenosis. JACC: Cardiovascular Imaging, 2019, 12, 203-205.	5.3	9
67	Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2471-2476.	0.8	39
68	Evolution of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2018, 19, 622-629.	1.2	40
69	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. European Heart Journal, 2018, 39, 39-46.	2.2	261
70	Quantitative Definition of Severe Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2018, 72, 2934-2935.	2.8	15
71	Lipid profile and longâ€term outcome in premature myocardial infarction. European Journal of Clinical Investigation, 2018, 48, e13008.	3.4	18
72	Polyunsaturated fatty acids supplementation impairs antiâ€oxidant highâ€density lipoprotein function in heart failure. European Journal of Clinical Investigation, 2018, 48, e12998.	3.4	9

#	Article	IF	CITATIONS
73	Immunomodulatory treatment for lymphocytic myocarditis—a systematic review and meta-analysis. Heart Failure Reviews, 2018, 23, 573-581.	3.9	22
74	Long-term outcome and risk assessment in premature acute myocardial infarction: A 10-year follow-up study. International Journal of Cardiology, 2017, 240, 37-42.	1.7	15
75	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. Journal of the American Heart Association, 2017, 6, .	3.7	13
76	Refining Long-Term Prediction of Cardiovascular Risk in Diabetes – The VILDIA Score. Scientific Reports, 2017, 7, 4700.	3.3	11
77	Impaired antioxidant HDL function is associated with premature myocardial infarction. European Journal of Clinical Investigation, 2015, 45, 731-738.	3.4	21
78	Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. Journal of Clinical Lipidology, 2015, 9, 801-806.e1.	1.5	45
79	Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (â‰#€ƒ40 years of age). European Journal of Clinical Investigation, 2012, 42, 631-636.	3.4	59

Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<=40 years of) Tj ETQq0 0 0 rgBT $_{2.2}^{1}$ Overlock 10 Tf 50